1443 related articles for article (PubMed ID: 27358547)
1. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
[TBL] [Abstract][Full Text] [Related]
2. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
3. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
Pashkov V; Soloviov A; Olefir A
Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
[TBL] [Abstract][Full Text] [Related]
4. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
5. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
[TBL] [Abstract][Full Text] [Related]
6. Regulatory pathways for vaccines for developing countries.
Milstien J; Belgharbi L
Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
[TBL] [Abstract][Full Text] [Related]
7. How the quality of essential medicines is perceived and maintained through the pharmaceutical supply chain: A perspective from stakeholders in Nigeria.
Amadi C; Tsui EK
Res Social Adm Pharm; 2019 Nov; 15(11):1344-1357. PubMed ID: 30509851
[TBL] [Abstract][Full Text] [Related]
8. [Falsified medicines in parallel trade].
Muckenfuß H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1208-1213. PubMed ID: 28905079
[TBL] [Abstract][Full Text] [Related]
9. Legal Uncertainty-The Gray Area around Substandard Medicines: Where Public Health Meets Law.
Olliaro E; Olliaro P; Ho CWL; Ravinetto R
Am J Trop Med Hyg; 2020 Feb; 102(2):262-267. PubMed ID: 31746313
[TBL] [Abstract][Full Text] [Related]
10. An exploratory assessment of the legislative framework for combating counterfeit medicines in South Africa.
Moshoeshoe RJ; Enslin GM; Katerere DR
J Pharm Policy Pract; 2022 Jan; 15(1):3. PubMed ID: 34986899
[TBL] [Abstract][Full Text] [Related]
11. From courts to markets: New evidence on enforcement of pharmaceutical bans in India.
Chatterjee C; Mohapatra DP; Estay M
Soc Sci Med; 2019 Sep; 237():112480. PubMed ID: 31425968
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the magnitude and contributing factors of expired medicines in the public pharmaceutical supply chains of Western Ethiopia.
Diriba G; Hasen G; Tefera Y; Suleman S
BMC Health Serv Res; 2023 Jul; 23(1):791. PubMed ID: 37491251
[TBL] [Abstract][Full Text] [Related]
13. Spurious and counterfeit drugs: a growing industry in the developing world.
Gautam CS; Utreja A; Singal GL
Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical counseling: Between evidence-based medicine and profits.
Egorova SN; Akhmetova T
Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
[TBL] [Abstract][Full Text] [Related]
15. [The network of official medicines control laboratories].
Buchheit KH; Wanko R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
[TBL] [Abstract][Full Text] [Related]
16. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
[TBL] [Abstract][Full Text] [Related]
17. Stopping murder by medicine: introducing the Model Law on Medicine Crime.
Attaran A
Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):127-132. PubMed ID: 25897071
[TBL] [Abstract][Full Text] [Related]
18. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
[No Abstract] [Full Text] [Related]
19. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
20. [Quality of medicines in least developed countries].
Videau JY
Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
